Raras
Buscar doenças, sintomas, genes...
Neoplasia endócrina múltipla, tipo 2A
ORPHA:247698CID-10 · D44.8CID-11 · 2F7A.0OMIM 171400DOENÇA RARA

Uma doença genética que aumenta a chance de desenvolver tumores, transmitida de forma autossômica dominante. Ela é causada por mutações no gene RET e é caracterizada por um risco maior de ter câncer medular de tireoide, feocromocitoma (um tumor nas glândulas suprarrenais) e hiperparatireoidismo (quando as glândulas paratireoides funcionam demais).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma doença genética que aumenta a chance de desenvolver tumores, transmitida de forma autossômica dominante. Ela é causada por mutações no gene RET e é caracterizada por um risco maior de ter câncer medular de tireoide, feocromocitoma (um tumor nas glândulas suprarrenais) e hiperparatireoidismo (quando as glândulas paratireoides funcionam demais).

Pesquisas ativas
3 ensaios
16 total registrados no ClinicalTrials.gov
Publicações científicas
608 artigos
Último publicado: 2026 Mar-Apr
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D44.8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
5 sintomas
🫘
Rins
4 sintomas
🫃
Digestivo
1 sintomas
🧬
Pele e cabelo
1 sintomas

+ 11 sintomas em outras categorias

Características mais comuns

100%prev.
Nódulo tireoidiano
Frequência: 2/2
100%prev.
Calcitonina elevada
Frequência: 2/2
83%prev.
Hiperparatireoidismo
Frequência: 10/12
75%prev.
Epinefrina urinária elevada
Frequência: 36/48
58%prev.
Ácido vanilmandélico urinário elevado
Frequência: 28/48
58%prev.
Norepinefrina urinária elevada
Frequência: 28/48
22sintomas
Muito frequente (3)
Frequente (9)
Ocasional (4)
Sem dados (6)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 22 características clínicas mais associadas, ordenadas por frequência.

Nódulo tireoidianoThyroid nodule
Frequência: 2/2100%
Calcitonina elevadaElevated calcitonin
Frequência: 2/2100%
HiperparatireoidismoHyperparathyroidism
Frequência: 10/1283%
Epinefrina urinária elevadaElevated urinary epinephrine
Frequência: 36/4875%
Ácido vanilmandélico urinário elevadoElevated urinary vanillylmandelic acid
Frequência: 28/4858%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico608PubMed
Últimos 10 anos200publicações
Pico202139 papers
Linha do tempo
2026Hoje · 2026🧪 2006Primeiro ensaio clínico📈 2021Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição.

Autosomal dominant
RETProto-oncogene tyrosine-protein kinase receptor RetDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation in response to glia cell line-derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15) (PubMed:20064382, PubMed:20616503, PubMed:20702524, PubMed:21357690, PubMed:21454698, PubMed:24560924, PubMed:28846097, PubMed:28846099, PubMed:28953886, PubMed:31118272). In contrast to most receptor tyrosine kinases, RET requires not onl

LOCALIZAÇÃO

Cell membraneEndosome membrane

VIAS BIOLÓGICAS (4)
RET signalingFormation of the ureteric budFormation of the nephric ductNPAS4 regulates expression of target genes
MECANISMO DE DOENÇA

Hirschsprung disease 1

A disorder of neural crest development characterized by absence of enteric ganglia along a variable length of the intestine. It is the most common cause of congenital intestinal obstruction. Early symptoms range from complete acute neonatal obstruction, characterized by vomiting, abdominal distention and failure to pass stool, to chronic constipation in the older child.

EXPRESSÃO TECIDUAL(Tecido-específico)
Substância negra
6.3 TPM
Pituitária
4.8 TPM
Cerebelo
4.0 TPM
Cólon sigmoide
4.0 TPM
Brain Frontal Cortex BA9
3.8 TPM
OUTRAS DOENÇAS (12)
multiple endocrine neoplasia type 2Bpheochromocytomafamilial medullary thyroid carcinomamultiple endocrine neoplasia type 2A
HGNC:9967UniProt:P07949

Medicamentos aprovados (FDA)

1 medicamento encontrado nos registros da FDA americana.

💊 Famotidine (FAMOTIDINE)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

534 variantes patogênicas registradas no ClinVar.

🧬 RET: NM_020975.6(RET):c.2940-1G>A ()
🧬 RET: NM_020975.6(RET):c.206del (p.Gly69fs) ()
🧬 RET: NM_020975.6(RET):c.3039+1G>A ()
🧬 RET: NM_020975.6(RET):c.1658G>T (p.Arg553Met) ()
🧬 RET: NM_020975.6(RET):c.249C>A (p.Asn83Lys) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 781 variantes classificadas pelo ClinVar.

781
Benigna (100.0%)
VARIANTES MAIS SIGNIFICATIVAS
RET: NM_020975.6(RET):c.1875C>A (p.Ile625=) [Benign]
LOC130003710: NM_020975.6(RET):c.2801+10G>T [Likely benign]
RET: NM_020975.6(RET):c.2016T>C (p.Ala672=) [Benign]
RET: NM_020975.6(RET):c.1548C>G (p.Pro516=) [Benign/Likely benign]
RET: NM_020975.6(RET):c.1880-17A>G [Likely benign]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 22
1Fase 11
·Pré-clínico5
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 8 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Neoplasia endócrina múltipla, tipo 2A

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

3 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

16 ensaios clínicos encontrados, 3 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
153 papers (10 anos)
#1

Advanced disease and biochemical phenotype shift in multiple endocrine neoplasia type 2A-related pheochromocytoma.

JCEM case reports2026 Mar

The incidence of metastatic recurrence in multiple endocrine neoplasia type 2 (MEN2)-related pheochromocytoma is low, and reports are scarce. Moreover, there are no reports detailing changes in biochemical findings at the time of metastatic recurrence. We describe here the case of a woman in her 40s with MEN2-related pheochromocytoma. She exhibited an increase in spot urine normetanephrine levels 2 years and 8 months after laparoscopic right adrenalectomy for right pheochromocytoma, leading to the diagnosis of peritoneal dissemination and distant metastasis. She underwent chemotherapy, which was ineffective, and died 3 years and 2 months after the initial surgery. Metastasis and recurrence of MEN2-related pheochromocytoma are rare, and a change in the biochemical phenotype is also uncommon. Therefore, we report the clinical course of this case in detail.

#2

Rare cases in two Chinese MEN2A families with RET C634Y germline mutation-a homozygous female patient and heterozygous identical twins: a systematic review of literature.

Frontiers in endocrinology2026

Germline RET-p.C634Y heterozygous mutations are predominant in MEN2A, but homozygous cases and MEN2A-affected identical twins remain poorly characterized. We report two MEN2A families-a homozygous female patient and heterozygous male twins, all with RET-p.C634Y mutations and classic MEN2A manifestations. A systematic review identified 18 homozygous cases from 10 families, involving exons 11, 14, and 15, containing nine types of mutations, presenting a female (55.6%) and moderate-risk mutation (61.1%) predominance. Overall, 83.3% of the 18 patients with homozygous mutations and 30.6% of the 49 patients with heterozygous mutations from the same generation had medullary thyroid carcinoma (MTC). The homozygous mutations had a higher penetrance rate of MTC (P < 0.001) and rates of node-positive metastasis (8/15 vs. 1/15, P = 0.017). However, the comparison of the mean age at initial MTC diagnosis between patients with homozygous and heterozygous mutations [33.40 ± 17.97 (5-59) vs. 39.60 ± 12.94 (14-61) years], as well as in moderate-risk and high-risk patients with homozygous mutations [36.89 ± 16.21 (13-59) vs. 28.17 ± 20.72 (5-56) years], showed no significant differences (all P > 0.05). Additionally, the mean age at diagnosis and the incidence of pheochromocytoma did not differ significantly [(37.75 ± 18.43) vs. (39.5 ± 3.54); 27.8% vs. 13.3%; all P > 0.05]. Clustered data for identical twins diagnosed with MEN2 were also analyzed, including one with MEN2A and two with MEN2B. All three pairs of identical twins exhibited varying clinical presentations, expressivity of MEN2-related MTC and/or pheochromocytoma, and associated biomarker levels. Homozygous MEN2A accelerates MTC onset and increases metastasis risk, but there is no evidence of association with the development of pheochromocytoma. Consanguineous marriage could increase homozygosity in offspring and the number of affected individuals. Expressivity and clinical progression can vary even with the same genetic backgrounds, and identical twins should also be subject to individual management.

#3

Persistent Hypercalcemia: Diagnostic Complexity With Multiglandular Hyperparathyroidism, Renal Cell Carcinoma, and Hereditary Tumor Features.

Cureus2026 Jan

Persistent hypercalcemia after parathyroidectomy is a diagnostic challenge that requires careful evaluation beyond the parathyroid glands. We describe the case of a 76-year-old man with chronic kidney disease, resistant hypertension, and vestibular schwannoma who presented with weakness, constipation, and new, dark, raised lesions across his back. He reported undergoing parathyroidectomy one year earlier for presumed primary hyperparathyroidism, after which his hypercalcemia persisted. On admission, serum calcium was 13.1 mg/dL (reference = 8.5-10.5 mg/dL), and examination revealed numerous seborrheic keratoses across his posterior thoracolumbar region, consistent with the Leser-Trélat sign. A Tc-99m sestamibi scan localized a left inferior parathyroid adenoma. MRI of the abdomen revealed a 4.1 × 3.6 × 3.1 cm enhancing posterior right renal mass consistent with renal cell carcinoma (RCC). Further history revealed long-term thiazide diuretic use and consumption of one gallon of milk every other day. He was treated with intravenous fluids, zoledronic acid, and calcitonin with symptomatic improvement and was referred to a tertiary center for surgical evaluation. Persistent hypercalcemia after parathyroidectomy is most often due to multiglandular disease, but it may coexist with other etiologies. This patient's concurrent parathyroid adenoma, RCC, thiazide use, and high calcium intake illustrate multifactorial hypercalcemia. Additionally, vestibular schwannoma, cutaneous lesions, and resistant hypertension suggest a possible hereditary tumor syndrome such as multiple endocrine neoplasia type 2A, neurofibromatosis type 2, or von Hippel-Lindau disease. This case highlights the risk of cognitive anchoring when hypercalcemia is attributed to a single pathology. Instead, a broad differential should be maintained, including concurrent malignancy or inherited syndromes. Early recognition of overlapping etiologies is essential to prevent delayed diagnosis or missed malignancy in patients with persistent hypercalcemia.

#4

Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A.

Endocrine-related cancer2026 Jan 01

Thyroidectomy is recommended for patients with multiple endocrine neoplasia type 2A (MEN2A). American Thyroid Association 2015 guidelines recommend follow-up of calcitonin values after thyroidectomy. The aim of this study was to determine the natural course of calcitonin levels after total thyroidectomy (TTx) in MEN2A patients. Patients with MEN2A who underwent TTx between 1993 and 2019 and had multiple postoperative calcitonin measurements were retrospectively included from our referral center. Long-term serial calcitonin measurements and clinical outcomes were correlated to the first postoperative calcitonin, histopathology and type of TTx (prophylactic versus non-prophylactic). Fifty-two patients underwent TTx after 1993 at a median age of 10 years (range 0-71). Of these, 23 (44%) had no MTC and 29 (56%) had MTC. The median follow-up time was 12 years (range 3-30). Thirty-eight patients had an 'undetectable' first postoperative calcitonin, seven 'within reference range' and seven 'above reference range'. Of the 38 patients with an 'undetectable' first postoperative calcitonin, 32 remained 'undetectable'. All 21 patients without MTC and 'undetectable' first postoperative calcitonin remained 'undetectable'. Of the 17 patients with MTC and 'undetectable' first postoperative calcitonin, 11 remained 'undetectable' and none developed structural recurrence. Twenty-two of the 25 patients undergoing prophylactic thyroidectomy had repeated 'undetectable' measurements. Persistent MTC or structural recurrence occurred in six patients; all had MTC, had a detectable first postoperative calcitonin and underwent non-prophylactic TTx. In conclusion, the long-term serial calcitonin values remain undetectable in the majority of the patients with an undetectable first postoperative calcitonin. Biochemical follow-up for patients without MTC and an undetectable first postoperative calcitonin may not be necessary.

#5

Redefining the prevalence of different clinical variants in MEN2A and their correlation with RET germline mutations: a single-center series and experience.

Endocrine-related cancer2026 Jan 01

Multiple endocrine neoplasia type 2 (MEN2) is caused by germline RET mutations and is characterized by the presence of medullary thyroid cancer (MTC) associated or not with other endocrine neoplasias. MEN2 is classified as MEN2A, including different variants, and MEN2B. The aim of the present study was to evaluate the impact of the RET genetic screening in redefining the prevalence of the different MEN2 variants inside the MEN2A group. This study included 223 MEN2 families: 202 MEN2A (55 MEN2A classical, 3 MEN2A + lichen cutaneous amyloidosis (CLA), 5 MEN2A + Hirschsprung disease (HD) and 139 FMTC variants) and 21 MEN2B. RET germline mutations found in MEN2A classical variant, as well as in MEN2A + CLA and MEN2A + HD, were the 'high-risk' category in most cases, while only 5/139 RET-mutated FMTC families showed a 'high-risk' category mutation. The most frequent mutation in the FMTC variant was the p.Val804Met (62/139). Among all, 116 families had a known history of hereditary disease (group A) at diagnosis and 107 had an apparently sporadic form of MTC (group B). Different MEN2A variants and RET ATA risk level category mutations were observed in the two groups. In conclusion, we demonstrated that the FMTC is the most prevalent MEN2A variant; 'moderate-risk' RET mutations, particularly non-cysteine mutations, are almost exclusively present in the FMTC variant; about 50% of hereditary MTC kindreds are primarily discovered by the RET genetic screening, confirming the clinical utility of performing this analysis in all cases of MTC.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC295 artigos no totalmostrando 198

2026

Advanced disease and biochemical phenotype shift in multiple endocrine neoplasia type 2A-related pheochromocytoma.

JCEM case reports
2026

Rare cases in two Chinese MEN2A families with RET C634Y germline mutation-a homozygous female patient and heterozygous identical twins: a systematic review of literature.

Frontiers in endocrinology
2026

Persistent Hypercalcemia: Diagnostic Complexity With Multiglandular Hyperparathyroidism, Renal Cell Carcinoma, and Hereditary Tumor Features.

Cureus
2026

Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A.

Endocrine-related cancer
2025

RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.

Genes
2026

Redefining the prevalence of different clinical variants in MEN2A and their correlation with RET germline mutations: a single-center series and experience.

Endocrine-related cancer
2026

[Integration of Molecular, Genetic, and Surgical Evidence Into the Indication Criteria for Preventive Thyroid Surgery].

Zentralblatt fur Chirurgie
2025

Presentation of multiple endocrine neoplasia type 2A-associated ectopic cushing's syndrome: case report and a systematic review.

Frontiers in endocrinology
2025

Untying the Next Genetic Thread in a Family With MEN2A Syndrome: A Case Report.

Clinical case reports
2026

Medullary thyroid carcinoma exclusively associated with a homozygous RET V778I pathogenic variant: a case report with review of literature.

Endocrine journal
2025

Genotype-phenotype correlations of germline mutations in exon 10 of the RET proto-oncogene from 14 MEN2A families of Ethnic Han Chinese.

PloS one
2025

Do Prognostic Differences Exist Among High-Risk RET Mutations? A Comparison of Outcomes Between the RET C634R and Other C634 Mutations in Hereditary Medullary Thyroid Carcinoma.

Thyroid : official journal of the American Thyroid Association
2025

Multifocality and bilaterality in medullary thyroid cancer: basis for a proof-of-concept safety of lobectomy.

European thyroid journal
2025

A Comparative Study on the Multidimensional Features of Hereditary and Sporadic Medullary Thyroid Carcinoma Patients: A Single-Center Retrospective Study.

Medicina (Kaunas, Lithuania)
2025

Geospatial inheritance across the breath of the RET mutational landscape of multiple endocrine neoplasia 2A.

Endocrine
2025

RET (C620R) Mutation in a Hirschsprung Disease Family: A Case Report Unveiling Asymptomatic Pheochromocytoma and Unmanifested Medullary Thyroid Carcinoma.

Cureus
2025

Medullary Thyroid Cancer Risk and Mortality in Carriers of Incidentally Identified MEN2A RET Variants.

JAMA network open
2025

Multiple endocrine neoplasia type 2A: a diagnostic challenge case report.

Annals of medicine and surgery (2012)
2025

Partial adrenalectomy for pheochromocytoma in the multiple endocrine neoplasia type 2 population: Time to reconsider?

Surgery
2025

Multicentric B-cell lymphoma, phaeochromocytoma and amyloid-rich thyroid carcinoma in a common warthog (Phacochoerus africanus): a case of multiple endocrine neoplasia type 2?

Journal of comparative pathology
2025

MEN2: surgical precision in the era of precision medicine.

Endocrine-related cancer
2025

Population Prevalence of the Major Thyroid Cancer-Associated Syndromes.

The Journal of clinical endocrinology and metabolism
2025

Management and Long-Term Monitoring of a Young Patient with Pheochromocytoma and RET Mutation: A Case Report.

International medical case reports journal
2025

Prevalence and genetics of "de novo" MEN2 syndromes.

The Journal of clinical endocrinology and metabolism
2025

Challenging Perioperative Management of a MEN2A Syndrome Patient Complicated by Eisenmenger Syndrome.

Turkish journal of anaesthesiology and reanimation
2025

Post-surgical natural history of MEN2A with RET C634R mutation and bilateral cervical node metastasis: a case report.

Annals of medicine and surgery (2012)
2025

Approach to the Patient: Hereditary Medullary Thyroid Carcinoma.

The Journal of clinical endocrinology and metabolism
2025

Primary Hyperparathyroidism in MEN2 Syndromes.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2025

Pheochromocytoma in MEN2.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2025

Hereditary Medullary Thyroid Cancer: Genotype-Phenotype Correlation.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2025

Epidemiology, Clinical Presentation, and Diagnosis of Medullary Thyroid Carcinoma.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2025

Incidence and distribution of neck node metastases in hereditary vs. sporadic medullary thyroid cancer at basal calcitonin serum levels ≤100 pg/ml: 30-year experience.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2025

RET C611Y Germline Variant in Multiple Endocrine Neoplasia Type 2A in Denmark 1930-2021: A Nationwide Study.

Cancers
2025

Proteomic Profiling of Medullary Thyroid Cancer Identifies CAPN1 as a Key Regulator of NF1 and RET Fueled Growth.

Thyroid : official journal of the American Thyroid Association
2024

[Metastatic pheochromocytoma in multiple endocrine neoplasia type 2A].

Problemy endokrinologii
2025

Natural history of medullary thyroid carcinoma in MEN 2 patients carrying a variant at codon 804 in the RET proto-oncogene: A study by the French Neuroendocrine Tumor Group (GTE).

Annales d'endocrinologie
2024

Synchronous transperitoneal robotic-assisted bilateral cortical-sparing adrenalectomy for pheochromocytomas in a patient with multiple endocrine neoplasia type 2a (MEN2A) syndrome: a case report.

Gland surgery
2025

Chapter 6: Syndromic primary hyperparathyroidism.

Annales d'endocrinologie
2025

Remission of Insulin-Dependent Diabetes Mellitus in Multiple Endocrine Neoplasia Type 2A After Adrenalectomy.

JCEM case reports
2025

Genotype-Phenotype Correlations in the Hyperparathyroidism-Jaw Tumor Syndrome.

The Journal of clinical endocrinology and metabolism
2025

RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly.

Endocrine-related cancer
2025

Dissection of RET p.M918T-driven progression of hereditary vs. sporadic medullary thyroid cancer.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2025

Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma.

Thyroid : official journal of the American Thyroid Association
2024

Robot-Assisted Surgery and Multigene Panel Testing for Pheochromocytoma and Paraganglioma Syndrome.

Cureus
2025

Living with a RET gene mutation: patient perspectives.

Endocrine-related cancer
2025

Cellular mechanisms of RET receptor dysfunction in multiple endocrine neoplasia 2.

Endocrine-related cancer
2024

Sporadic and Familial Medullary Thyroid Carcinoma: A Retrospective Single Center Study on Presentation and Outcome.

Endocrine research
2024

Genotype/phenotype correlations in multiple endocrine neoplasia type 2.

Endocrine-related cancer
2024

Thyroid Malignancy and Cutaneous Lichen Amyloidosis: Key Points Amid RET Pathogenic Variants in Medullary Thyroid Cancer/Multiple Endocrine Neoplasia Type 2 (MEN2).

International journal of molecular sciences
2024

The Long-Term Cure of Patients With Hereditary Medullary Thyroid Carcinoma: 40 Years of Follow-Up in a Single Center.

Deutsches Arzteblatt international
2024

Origin and impact of multifocal growth in sporadic vs. hereditary medullary thyroid cancer.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2024

Multiple Endocrine Neoplasia Type 1, Type 2A, and Type 2B.

Primary care
2024

Oncological features of sporadic vs. hereditary pediatric medullary thyroid cancer.

Endocrine
2024

Critically evaluated key points on hereditary medullary thyroid carcinoma.

Frontiers in endocrinology
2024

C634Y mutation in RET-induced multiple endocrine neoplasia type 2A: A case report.

World journal of clinical cases
2024

[30 years of prophylactic thyroidectomy for hereditary medullary thyroid cancer : A milestone in translational medicine].

Chirurgie (Heidelberg, Germany)
2024

Two sisters diagnosed with familial paraganglioma syndrome type 1 (FPGL1) and multiple endocrine neoplasia type 2A (MEN2A).

World journal of surgical oncology
2024

Genotype-specific development of MEN 2 constituent components in 683 RET carriers.

Endocrine-related cancer
2024

[Multiple endocrine neoplasia and very early onset inflammatory bowel disease. An unexpected association].

Medicina
2025

Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.

The Journal of clinical endocrinology and metabolism
2024

Genetic diagnosis of endocrine disorders in Cyprus through the Cyprus Institute of Neurology and Genetics: an ENDO-ERN Reference Center.

Orphanet journal of rare diseases
2024

Developing Dynamic Structure-Based Pharmacophore and ML-Trained QSAR Models for the Discovery of Novel Resistance-Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI Analysis.

ChemMedChem
2024

Accelerated MEN2A in homozygous RET carriers in the context of consanguinity.

European journal of endocrinology
2024

Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-Term Outcomes in 144 Patients Over 6 Decades.

The Journal of clinical endocrinology and metabolism
2024

RET 634 germline/gonadal mosaicism generating a second pathogenic amino acid change in multiple endocrine neoplasia type 2A.

American journal of medical genetics. Part A
2023

The role of prophylactic parathyroidectomy during thyroidectomy for MTC in patients with MEN2A syndrome.

Folia medica
2024

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.

Annales d'endocrinologie
2024

The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype?

International journal of molecular sciences
2024

Rare and aggressive metastatic pheochromocytoma recurrence in a patient with MEN 2A syndrome.

BMJ case reports
2023

[A Case Report of Multiple Endocrine Neoplasia Type 2A(MEN2A)Diagnosed with Medullary Thyroid Carcinoma].

Gan to kagaku ryoho. Cancer &amp; chemotherapy
2024

Diagnostic and Surgical Challenges Associated With Sporadic Multiple Endocrine Neoplasia 2A Presenting as Non-syndromic Primary Hyperparathyroidism.

The American surgeon
2024

[Individualization of treatment in sporadic and hereditary medullary thyroid cancer].

Chirurgie (Heidelberg, Germany)
2024

Comparing nodal with primary tumor desmoplasia uncovers metastatic patterns in multiple endocrine neoplasia 2B.

European journal of endocrinology
2023

Clinical characteristics of a large familial cohort with Medullary thyroid cancer and germline Cys618Arg RET mutation in an Israeli multicenter study.

Frontiers in endocrinology
2023

Left anterior descending artery disease in a 27-year-old with multiple endocrine neoplasia, type 2A: A case report.

SAGE open medical case reports
2024

Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results.

Current opinion in oncology
2024

Impact of Early Diagnostic and Therapeutic Interventions and Clinical Course in Children and Adolescents with Multiple Endocrine Neoplasia Types 1 and 2.

Experimental and clinical endocrinology &amp; diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
2023

[Surgical treatment of pheochromocytoma].

Problemy endokrinologii
2024

Multiple endocrine neoplasia type 2A syndrome presenting with corneal nerve thickening.

QJM : monthly journal of the Association of Physicians
2023

Germline founder variant c.1998delinsTTCT in the RET oncogene: a cohort study in 15 Belgian families.

European journal of endocrinology
2023

No relevant spectator impact on home advantage in male and female professional volleyball - A longitudinal multilevel logistic model analysis over 25 years.

Psychology of sport and exercise
2023

Pediatric head and neck manifestations associated with multiple endocrine neoplasia syndromes.

International journal of pediatric otorhinolaryngology
2023

Clinic Heterogeneity and Management of Pediatric Patients With Germline RET Proto-oncogene Mutation: Single-center Experience.

Journal of pediatric hematology/oncology
2023

Remote Recurrent Primary Hyperparathyroidism in Auto-Transplanted Tissue.

Cureus
2023

Clinical presentation of MEN 2A in index vs. non-index patients.

Endocrine
2023

Incidence of medullary thyroid carcinoma and Hirschsprung disease based on the cosmos database.

Pediatric surgery international
2023

Benzene and cause-specific mortality in an Italian national cohort of exposed workers through a proportions analysis.

Epidemiologia e prevenzione
2023

[Pheochromocytoma associated with primary hyperparathyroidism and type 1 neurofibromatosis].

Khirurgiia
2024

Lived experiences of undergoing regular tumor screening in patients with multiple endocrine neoplasia types 1 and 2 (MEN1/MEN2).

Journal of genetic counseling
2023

Diagnosis and treatment of bilateral adrenal pheochromocytoma with RET gene mutation combined with medullary sponge kidney: A case report.

Medicine
2023

A MEN-2A Case Developing Transient Adrenal Insufficiency after Unilateral Pheochromocytoma Surgery.

Journal of clinical practice and research
2023

Diagnostic Utility of Menin Immunohistochemistry in Patients With Multiple Endocrine Neoplasia Type 1 Syndrome.

The American journal of surgical pathology
2023

Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing.

Endocrine
2023

[A case of multiple endocrine neoplasia syndrome type 2A combined with autoimmune polyendocrine syndrome type Ⅲ].

Zhonghua nei ke za zhi
2023

Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A in Denmark 1930–2021: A Nationwide Population-Based Retrospective Study.

Cancers
2023

The Changing Face of Multiple Endocrine Neoplasia 2A: From Symptom-Based to Preventative Medicine.

The Journal of clinical endocrinology and metabolism
2023

A Familial Case of Multiple Endocrine Neoplasia 2A: From Morphology to Genetic Alterations Penetration in Three Generations of a Family.

Diagnostics (Basel, Switzerland)
2023

The protean role of Val804Met RET mutation in thyroid neoplasms: An example of a "MEN2C" syndrome?

Pathology, research and practice
2023

["Graded early warning system" of RET germline mutation carriers in MEN2A/MEN2B families and total thyroidectomy (report of 7 cases)].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
2023

[Hereditary medullary thyroid cancer].

Chirurgie (Heidelberg, Germany)
2023

Familial parathyroid tumours-comparison of clinical profiles between syndromes.

Journal of endocrinological investigation
2023

Pediatric Thyroidectomy: Experience From a Portuguese Hospital.

Cureus
2023

Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance.

Endocrine
2023

Menin Loss in Pheochromocytoma of Multiple Endocrine Neoplasia Type 1.

Endocrine pathology
2023

Temporal trends in referrals of RET gene carriers for neck surgery to a tertiary surgical center in the era of international management guidelines.

Endocrine
2022

Progressive metastatic pheochromocytoma induced by multiple endocrine neoplasia type 2A with a lethal outcome.

IJU case reports
2022

Calvarial metastasis from malignant pheochromocytoma associated with multiple endocrine neoplasia.

Surgical neurology international
2022

[The trends in early precision diagnosis and treatment strategies of multiple endocrine neoplasia type 2].

Zhonghua wai ke za zhi [Chinese journal of surgery]
2022

Multiple endocrine neoplasia type 2 (MEN2) and RET specific modifications of the ACMG/AMP variant classification guidelines and impact on the MEN2 RET database.

Human mutation
2023

Pheochromocytoma recurrence in hereditary disease: does a cortical-sparing technique increase recurrence rate?

Surgery
2022

[Correlation analysis of clock genes and MEN2 medullary thyroid carcinoma].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
2022

Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis.

Cancer research
2023

Medullary thyroid cancer with RET V804M mutation: more indolent than expected?

Surgery
2022

[Clinical and genetic analysis of seven Chinese pedigrees affected with multiple endocrine neoplasia type 2A with cutaneous lichen amyloidosis].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2022

A Case Study of Multiple Endocrine Neoplasia Type 2A.

Cureus
2022

Invited Commentary: Less than Subtotal Parathyroidectomy for Multiple Endocrine Neoplasia Type 1 Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis.

World journal of surgery
2022

Unexpected structures formed by the kinase RET C634R mutant extracellular domain suggest potential oncogenic mechanisms in MEN2A.

The Journal of biological chemistry
2022

[Multiple, bilateral conjunctival tumors-A 27-year-old female patient with MEN2B].

Die Ophthalmologie
2022

RET gene mutational diagnosis and precision medicine in Mexico.

Gaceta medica de Mexico
2023

Elevated Calcitonin Levels in a Patient With a Pheochromocytoma: A Case Report.

The American surgeon
2022

Anesthesia and Outcome of 33 Surgeries in 24 Multiple Endocrine Neoplasia Type 2A (MEN2A) Patients: A National Rare Disease Center's Experience.

Frontiers in endocrinology
2022

Management of medullary carcinoma of the thyroid: a review.

The Journal of international medical research
2022

Medullary thyroid carcinoma: a narrative historical review.

Expert review of anticancer therapy
2022

Pheochromocytoma triggered by coronavirus disease 2019: a case report.

Journal of medical case reports
2022

Multiple endocrine neoplasia type 2 and autoimmune polyendocrine syndromes (type 1 diabetes mellitus and Graves' disease) in a 16-year-old male with Kabuki syndrome.

Endocrine journal
2022

RET c.1901G>A and Novel SLC12A3 Mutations in Familial Pheochromocytomas.

Genes
2022

Recurrent ipsilateral pheochromocytoma in carriers of RET p.Cys634 missense mutations.

Endocrine
2022

Multiple endocrine neoplasia type 4 & primary hyperparathyroidism: What the surgeon needs to know.

American journal of surgery
2022

Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.

Frontiers in endocrinology
2022

Simultaneous unilateral laparoscopic adrenalectomy for pheochromocytoma and thyroidectomy in MEN 2A and MEN 2B syndrome.

Endokrynologia Polska
2022

Susceptibility Genes and Chromosomal Regions Associated With Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Some Pathogenetic and Diagnostic Keys.

Frontiers in endocrinology
2022

MEN2A syndrome presenting as medullary thyroid cancer metastasizing into the pheochromocytoma.

Asian journal of surgery
2021

[Clinical and laboratory features of hereditary pheochromocytoma and paraganglioma].

Problemy endokrinologii
2022

Fractures in type 2 diabetes confer excess mortality: The Dubbo osteoporosis epidemiology study.

Bone
2022

Sex differences in MEN 2A penetrance and expression according to parental inheritance.

European journal of endocrinology
2022

Fibroblast Activation Protein Inhibitor Imaging and Therapy in a Patient With Multiple Endocrine Neoplasia Type 2A Syndrome.

Clinical nuclear medicine
2022

Surgical aspects and controversies in the management of medullary thyroid cancer.

Irish journal of medical science
2022

Quality of work community and workers' intention to retire.

International archives of occupational and environmental health
2021

Multiple endocrine neoplasia 2A presenting in a family with a history of Hirschprung's disease.

Oxford medical case reports
2021

Germline RET Leu56Met Variant Is Likely Not Causative of Multiple Endocrine Neoplasia Type 2.

Frontiers in endocrinology
2022

Updates on therapy for medullary thyroid cancer in 2021.

Annales d'endocrinologie
2022

Clinical features and signaling effects of RET D631Y variant multiple endocrine neoplasia type 2 (MEN2).

The Korean journal of internal medicine
2022

Preoperative calcitonin testing improves the diagnosis of medullary thyroid carcinoma in female and male patients.

European journal of endocrinology
2022

Clinical, Biochemical, Tumoural and Mutation Profile of VHL- and MEN2A-Associated Pheochromocytoma: A Comparative Study.

World journal of surgery
2021

Case Report: A Case of Moyamoya Syndrome Associated With Multiple Endocrine Neoplasia Type 2A.

Frontiers in endocrinology
2021

Laparoscopic resection of aortocaval paraganglioma diagnosed by serial increase in urinary metanephrines after bilateral adrenalectomy in a patient with multiple endocrine neoplasia type 2A.

IJU case reports
2021

How does nintedanib overcome cancer drug-resistant mutation of RET protein-tyrosine kinase: insights from molecular dynamics simulations.

Journal of molecular modeling
2021

Parathyroid Tumors: Molecular Signatures.

International journal of molecular sciences
2022

Medullary thyroid cancer and pheochromocytoma in MEN2A: are there parent of origin effects on disease expression?

Familial cancer
2022

State of the art and future directions in the systemic treatment of medullary thyroid cancer.

Current opinion in oncology
2021

Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.

Frontiers in endocrinology
2022

Controversy on the management of patients carrying RET p.V804M mutation.

Endocrine
2021

Calcitonin and complementary biomarkers in the diagnosis of hereditary medullary thyroid carcinoma in children and adolescents.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2022

Impact of RET Screening on the Management of Multiple Endocrine Neoplasia Type 2A: 10 Years Experience and Follow-Up in Three Families.

Endocrine, metabolic &amp; immune disorders drug targets
2021

Late-Onset Medullary Thyroid Cancer in a Patient with a Germline RET Codon C634R Mutation.

Diagnostics (Basel, Switzerland)
2021

Surgical Remission of Diabetes in a Patient With Mutation of RET Proto-Oncogene.

AACE clinical case reports
2021

Multiple endocrine neoplasia type 2: diagnostic challenges of a medullary thyroid carcinoma nodule.

Internal medicine journal
2021

A patient with RET D631Y mutation present with pheochromocytoma.

Clinical case reports
2021

Children with multiple endocrine neoplasia type 2B: Not tall and marfanoid, but short with normal body proportions.

Clinical endocrinology
2021

Elevated basal serum levels of calcitonin and simultaneous surgery of MEN2A-specific tumors.

Neoplasma
2020

New mutations associated with Hirschsprung disease.

Anales de pediatria
2021

Multiple endocrine neoplasia 2A with RET mutation p.Cys611Tyr: A case report.

Medicine
2021

Pheochromocytoma: A three-decade clinical experience in a multicenter study.

Revista clinica espanola
2021

Similar Stage-dependent Survival and Outcome in Sporadic and Hereditary Medullary Thyroid Carcinoma.

The Journal of clinical endocrinology and metabolism
2021

Invited Commentary: "Familial Non-Medullary Thyroid Carcinoma in Pediatric Age: Our Surgical Experience.".

World journal of surgery
2021

Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency.

Croatian medical journal
2021

Spectrum of Germline RET variants identified by targeted sequencing and associated Multiple Endocrine Neoplasia type 2 susceptibility in China.

BMC cancer
2020

Medullary thyroid cancer: molecular factors, management and treatment.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
2021

Management and results of thyroidectomies in pediatric patients with MEN 2 syndrome.

Journal of pediatric surgery
2022

Multiple endocrine neoplasia type 2: A review.

Seminars in cancer biology
2021

Functional impact of a germline RET mutation in alveolar rhabdomyosarcoma.

Cold Spring Harbor molecular case studies
2021

Case report of adrenocortical carcinoma associated with double germline mutations in MSH2 and RET.

American journal of medical genetics. Part A
2021

[A young male with multiple endocrine neoplasia type 2 misdiagnosed as viral myocarditis].

Zhonghua xin xue guan bing za zhi
2021

Hereditary Medullary Thyroid Carcinoma: Genotype, Phenotype and Outcomes in a North Indian Cohort.

World journal of surgery
2021

Pheochromocytoma in Multiple Endocrine Neoplasia Type 2.

Mayo Clinic proceedings
2021

Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates.

Endocrine pathology
2021

Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.

Endocrine pathology
2021

Timely diagnosis of multiple endocrine neoplasia 2B by identification of intestinal ganglioneuromatosis: a case series.

Endocrine
2021

Homozygosity for the pathogenic RET hotspot variant p.Cys634Trp: A consanguineous family with MEN2A.

European journal of medical genetics
2021

RMRP, RMST, FTX and IPW: novel potential long non-coding RNAs in medullary thyroid cancer.

Orphanet journal of rare diseases
2021

A rare RET mutation in an Indian pedigree with familial medullary thyroid carcinoma.

Indian journal of cancer
2021

Hereditary medullary thyroid carcinoma syndromes: experience from western India.

Familial cancer
2021

Diagnostic RET genetic testing in 1,058 index patients: A UK centre perspective.

Clinical endocrinology
2020

Multiple endocrine neoplasia-IIb with RET gene mutation p.M918T: A case report.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
2022

Molecular targets of tyrosine kinase inhibitors in thyroid cancer.

Seminars in cancer biology
2020

Preimplantation Genetic Testing of Multiple Endocrine Neoplasia Type 2A.

Frontiers in endocrinology
2021

Impact of gastrointestinal symptoms on quality of life in MEN2.

Clinical endocrinology
2020

[Surgical aspects of multiple endocrine neoplasia type 2].

Therapeutische Umschau. Revue therapeutique
2021

Predicting Outcomes in Sporadic and Hereditary Medullary Thyroid Carcinoma over Two Decades.

Thyroid : official journal of the American Thyroid Association
2020

Phaeochromocytoma recurrence in a patient with multiple endocrine neoplasia type 2A.

Journal of surgical case reports
2020

[Familial papillary thyroid cancer].

Orvosi hetilap
2021

A novel germline variant in RET gene resulting in an additional cysteine in a family with familial medullary thyroid carcinoma.

Familial cancer
2020

5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine.

Frontiers in endocrinology
2020

The synergy of germline C634Y and V292M RET mutations in a northern Chinese family with multiple endocrine neoplasia type 2A.

Journal of cellular and molecular medicine
2021

Lymph node metastasis in hereditary medullary thyroid cancer is independent of the underlying RET germline mutation.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2020

Laparoscopic transperitoneal left partial adrenalectomy for familial pheochromocytoma (with video).

Journal of visceral surgery
2020

Multiple endocrine neoplasia type 2A with cutaneous lichen amyloidosis.

BMJ case reports
2020

Expression and purification of the extracellular domain of wild-type humanRET and the dimeric oncogenic mutant C634R.

International journal of biological macromolecules
Ver todos os 295 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Neoplasia endócrina múltipla, tipo 2A.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Neoplasia endócrina múltipla, tipo 2A

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Advanced disease and biochemical phenotype shift in multiple endocrine neoplasia type 2A-related pheochromocytoma.
    JCEM case reports· 2026· PMID 41837230mais citado
  2. Rare cases in two Chinese MEN2A families with RET C634Y germline mutation-a homozygous female patient and heterozygous identical twins: a systematic review of literature.
    Frontiers in endocrinology· 2026· PMID 41727686mais citado
  3. Persistent Hypercalcemia: Diagnostic Complexity With Multiglandular Hyperparathyroidism, Renal Cell Carcinoma, and Hereditary Tumor Features.
    Cureus· 2026· PMID 41631080mais citado
  4. Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A.
    Endocrine-related cancer· 2026· PMID 41498511mais citado
  5. Redefining the prevalence of different clinical variants in MEN2A and their correlation with RET germline mutations: a single-center series and experience.
    Endocrine-related cancer· 2026· PMID 41404851mais citado
  6. Sarcoidosis-Induced Hypercalcemia in a Patient With Multiple Endocrine Neoplasia Type 2A (MEN2A) Syndrome Harboring the C609Y REarranged During Transfection (RET) Mutation.
    AACE Endocrinol Diabetes· 2026· PMID 41938302recente
  7. RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.
    Genes (Basel)· 2025· PMID 41465145recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:247698(Orphanet)
  2. OMIM OMIM:171400(OMIM)
  3. MONDO:0008234(MONDO)
  4. GARD:4881(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q604075(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Neoplasia endócrina múltipla, tipo 2A
Compêndio · Raras BR

Neoplasia endócrina múltipla, tipo 2A

ORPHA:247698 · MONDO:0008234
CID-10
D44.8 · Neoplasia de comportamento incerto ou desconhecido com comprometimento pluriglandular
CID-11
Ensaios
3 ativos
Início
Childhood
MedGen
UMLS
C1833921
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades